OCProDx test
over-treatment of prostate cancer
Atturos
treatment decision
effects of treatment
Organ-Confined Prostate cancer
technical performance of OCProDx
blood test
multiplexed protein diagnostic
multiplexed protein signature
blood protein signature
monitoring of disease progression
low risk disease
clinical performance
market size
existing diagnostic tools
key external consultants
key patient decisions
long term repeated monitoring
need significant
estimated gross profit margin
high value EU employment opportunities
radiation
drugs
half
commercialisation
Europe
impact
tests
capacity
Strategic planning
commercial setting
detailed business plan
Well-resourced laboratory
studies
surgery
founded UCD
company
serious issue
active surveillance
year
quality of life
compelling opportunity
reach
vast majority
best option
proposal